Clarius Group, LLC Lyell Immunopharma, Inc. Transaction History
Clarius Group, LLC
- $1.44 Billion
- Q4 2024
A detailed history of Clarius Group, LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Clarius Group, LLC holds 399,168 shares of LYEL stock, worth $231,517. This represents 0.02% of its overall portfolio holdings.
Number of Shares
399,168
Previous 399,168
-0.0%
Holding current value
$231,517
Previous $550,000
53.64%
% of portfolio
0.02%
Previous 0.04%
Shares
2 transactions
Others Institutions Holding LYEL
# of Institutions
120Shares Held
142MCall Options Held
18.1KPut Options Held
200-
Mwg Management Ltd. Washington, DC20.2MShares$11.7 Million30.81% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$8.75 Million13.96% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$8.75 Million42.56% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$7.83 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$5.84 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $144M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...